The Psychedelics as Medicine Report: Third Edition

The Psychedelics as Medicine Report: Third Edition provides unparalleled consumer insights and market intelligence from experts and industry leaders, helping investors cut through the noise and identify real opportunities.

The Psychedelics as Medicine Report: Third Edition examines

  • Proprietary insights from consumers and healthcare providers
  • Deep dives into the most transformative compounds and companies
  • Key regulations, transformative trends and commercial opportunities
  • Introduction
  • Definition and Scope
  • Executive Summary
  • Key Trends
  • Market Value
  • Legislation and Regulation
  • Consumer Attitudes
  • Healthcare Providers’ Attitudes
  • Spotlight on Health
  • Psychedelics – Timeline of Key Developments
  • Countries to Watch
  • Psychedelic Profiles
  • Key Psychedelics of Note
  • Psychedelics As Medicines – Potential Therapies
  • Psychedelics and Technology
  • Psychedelics per Country
  • Psychedelics and the Law
  • Patents and Intellectual Property
  • Therapists and Doctors
  • Psychedelic Research
  • Glossary
  • Research is at a tipping point
  • Psychedelics poised to treat many disorders
  • Therapy will be the name of the game
  • Legislation and regulation moving in the right direction
  • Patients and doctors are ready for change
  • Approval landscape
  • Projected growth of medical psychedelics market
  • The cost of illness
  • Economic health model
  • Mental health during the COVID-19 pandemic
  • Consumer’s take on psychedelics as medicine
  • The education opportunity
  • Psychedelics of choice
  • Influence of prior drug use on openness to psychedelic-assisted therapies
  • State of mental health: Healthcare workers
  • Psychedelic expertise of healthcare workers
  • Healthcare workers’ familiarity with psychedelic-assisted therapy
  • Therapy: The benefits and challenges
  • Healthcare workers’ attitudes towards the medical benefits of psychedelics
  • Influence of psychedelic use on practitioner views
  • Psychedelics coming out the closet
  • Novel ways of treating persistant problems
  • Total number of clinical trials
  • Key conditions
  • Percentage of mental health and substance use disorders
  • Facts about mental health conditions
  • Psychedelic history and future
  • Why psychedelics are different
  • Psilocybin
  • LSD
  • MDMA
  • Ketamine
  • Ibogaine
  • Ayahuasca
  • Salvia Divinorum
  • Mescaline
  • DMT
  • 5-MeO-DMT
  • Kratom
  • 2C-X
  • Nitrous Oxide
  • Australia
  • Brazil
  • Canada
  • China
  • Denmark
  • Germany
  • Ireland
  • Netherlands
  • Spain
  • Switzerland
  • United Kingdom
  • United States
  • Florian Brand – Co-founder and CEO, atai Life Sciences
  • George Goldsmith – Co-founder and CEO, COMPASS Pathways
  • Cosmo Feilding Mellen – CEO, Beckley Psytech
  • Dr Roger McIntyre – CEO, Braxia Scientific
  • Dr Reid Robison – Chief Medical Officer and Director, Novamind

In collaboration with

Data availability

Consumer Survey (2021) data split per country

Healthcare Survey (2021) data split per country

Become a psychedelic insider!

With a free Blossom membership you will always be in the know.

📰 Weekly newsletter about the psychedelic research

✔️ Unlimited access to our database and original articles

🖊️ Add (private) notes and comments to each page

Make an account